CIGB 300
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- CIGB 300
- DrugBank Accession Number
- DB16464
- Background
CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Peptides - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- P15-Tat
- External IDs
- CIGB 300
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
CIGB 300 is a peptide that inhibits protein casein kinase 2 (CK2) activity. It binds to the phospho-acceptors of CK2 substrates, preventing their phosphorylation by CK2. It is currently being investigated as an anti-cancer drug as CK2 is overexpressed in numerous cancers.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X6HMT2EDH9
- CAS number
- 1072877-99-6
References
- General References
- Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG: CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1. [Article]
- Perea SE, Baladron I, Valenzuela C, Perera Y: CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. Semin Oncol. 2018 Jan;45(1-2):58-67. doi: 10.1053/j.seminoncol.2018.04.006. Epub 2018 May 3. [Article]
- Sarduy MR, Garcia I, Coca MA, Perera A, Torres LA, Valenzuela CM, Baladron I, Solares M, Reyes V, Hernandez I, Perera Y, Martinez YM, Molina L, Gonzalez YM, Ancizar JA, Prats A, Gonzalez L, Casaco CA, Acevedo BE, Lopez-Saura PA, Alonso DF, Gomez R, Perea-Rodriguez SE: Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer. Br J Cancer. 2015 May 12;112(10):1636-43. doi: 10.1038/bjc.2015.137. Epub 2015 Apr 16. [Article]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Not Available Cervical Adenocarcinoma / Cervical Squamous Cell Carcinoma 1 somestatus stop reason just information to hide 2, 3 Terminated Treatment Nonrecurrent Condyloma / Recurrent Condyloma 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:43 / Updated at July 23, 2024 18:02